• Je něco špatně v tomto záznamu ?

Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review

A. Bazarkin, A. Morozov, A. Androsov, H. Fajkovic, JG. Rivas, N. Singla, S. Koroleva, JY. Teoh, AV. Zvyagin, SF. Shariat, B. Somani, D. Enikeev

. 2024 ; 25 (1) : 19-35. [pub] 20231215

Jazyk angličtina Země Spojené státy americké

Typ dokumentu systematický přehled, časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007738

PURPOSE OF REVIEW: The aim of the systematic review is to assess AI's capabilities in the genetics of prostate cancer (PCa) and bladder cancer (BCa) to evaluate target groups for such analysis as well as to assess its prospects in daily practice. RECENT FINDINGS: In total, our analysis included 27 articles: 10 articles have reported on PCa and 17 on BCa, respectively. The AI algorithms added clinical value and demonstrated promising results in several fields, including cancer detection, assessment of cancer development risk, risk stratification in terms of survival and relapse, and prediction of response to a specific therapy. Besides clinical applications, genetic analysis aided by the AI shed light on the basic urologic cancer biology. We believe, our results of the AI application to the analysis of PCa, BCa data sets will help to identify new targets for urological cancer therapy. The integration of AI in genomic research for screening and clinical applications will evolve with time to help personalizing chemotherapy, prediction of survival and relapse, aid treatment strategies such as reducing frequency of diagnostic cystoscopies, and clinical decision support, e.g., by predicting immunotherapy response. These factors will ultimately lead to personalized and precision medicine thereby improving patient outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007738
003      
CZ-PrNML
005      
20240423160223.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11934-023-01193-2 $2 doi
035    __
$a (PubMed)38099997
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bazarkin, Andrey $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
245    10
$a Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review / $c A. Bazarkin, A. Morozov, A. Androsov, H. Fajkovic, JG. Rivas, N. Singla, S. Koroleva, JY. Teoh, AV. Zvyagin, SF. Shariat, B. Somani, D. Enikeev
520    9_
$a PURPOSE OF REVIEW: The aim of the systematic review is to assess AI's capabilities in the genetics of prostate cancer (PCa) and bladder cancer (BCa) to evaluate target groups for such analysis as well as to assess its prospects in daily practice. RECENT FINDINGS: In total, our analysis included 27 articles: 10 articles have reported on PCa and 17 on BCa, respectively. The AI algorithms added clinical value and demonstrated promising results in several fields, including cancer detection, assessment of cancer development risk, risk stratification in terms of survival and relapse, and prediction of response to a specific therapy. Besides clinical applications, genetic analysis aided by the AI shed light on the basic urologic cancer biology. We believe, our results of the AI application to the analysis of PCa, BCa data sets will help to identify new targets for urological cancer therapy. The integration of AI in genomic research for screening and clinical applications will evolve with time to help personalizing chemotherapy, prediction of survival and relapse, aid treatment strategies such as reducing frequency of diagnostic cystoscopies, and clinical decision support, e.g., by predicting immunotherapy response. These factors will ultimately lead to personalized and precision medicine thereby improving patient outcomes.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a prostata $7 D011467
650    _2
$a lokální recidiva nádoru $x genetika $7 D009364
650    _2
$a umělá inteligence $7 D001185
650    12
$a nádory močového měchýře $x diagnóza $x genetika $x terapie $7 D001749
650    _2
$a recidiva $7 D012008
650    _2
$a biologické markery $7 D015415
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Morozov, Andrey $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Androsov, Alexander $u Department of Pediatric Surgery, Division of Pediatric Urology and Andrology, Sechenov University, Moscow, Russia
700    1_
$a Fajkovic, Harun $u Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Rivas, Juan Gomez $u Department of Urology, Clinico San Carlos University Hospital, Madrid, Spain
700    1_
$a Singla, Nirmish $u School of Medicine, Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD, USA
700    1_
$a Koroleva, Svetlana $u Clinical Institute for Children Health Named After N.F. Filatov, Sechenov University, Moscow, Russia
700    1_
$a Teoh, Jeremy Yuen-Chun $u Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
700    1_
$a Zvyagin, Andrei V $u Institute of Molecular Theranostics, Sechenov University, Moscow, Russia $u Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, Moscow, Russia
700    1_
$a Shariat, Shahrokh François $u Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Somani, Bhaskar $u Department of Urology, University Hospital Southampton, Southampton, United Kingdom
700    1_
$a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. dvenikeev@gmail.com $u Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. dvenikeev@gmail.com $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. dvenikeev@gmail.com $u Division of Urology, Rabin Medical Center, Petah Tikva, Israel. dvenikeev@gmail.com
773    0_
$w MED00207783 $t Current urology reports $x 1534-6285 $g Roč. 25, č. 1 (2024), s. 19-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38099997 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160220 $b ABA008
999    __
$a ok $b bmc $g 2081617 $s 1217505
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 1 $d 19-35 $e 20231215 $i 1534-6285 $m Current urology reports $n Curr Urol Rep $x MED00207783
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace